Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel anticonvulsant compound, has completed the first stage of pivotal IND-enabling Tox studies in rodent and non-rodent species.
“The recent results confirm what we already know about this exciting compound,” said Pawel Zolnierczyk, CEO. “We’re one step closer to bringing this effective therapeutic to a clinic trial, with the potential to significantly improve patients’ quality of life. Results of recent toxicological studies show that iQ-007 unique mechanism of action as a Positive Allosteric Modulator (PAM) of the EAAT2 neurotransporter, is a very promising therapeutic strategy, ‘triggering a human natural safety mechanism’ that allows for more efficient clearance of excess glutamate which in turn prevents neurotoxicity and seizures.”
iQ-007 is well tolerated and continues to demonstrate an impressive safety profile. iQure Pharma is looking forward to completing the IND-enabling tox study series, which will accelerate the preparation of the First in Human Phase 1 study.
About iQure Pharma:
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.
For more information, please contact pawel.zolnierczyk@iqurepharma.com.